GSK3395879
GSK3395879 is a TRPV4 antagonist that acts on hTRPV4 with an IC50 of 1 nM. GSK3395879 blocks agonist-induced TRPV4-mediated Ca2+ mobilization. GSK3395879 inhibits rat pulmonary edema induced by the TRPV4 agonist GSK1016790A (HY-19608). GSK3395879 can be used in research related to heart failure.
For research use only. We do not sell to patients.
- CAS No.: 2215852-91-6
- Formula: C20H15F4N3O5S
- Molecular Weight:485.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
hTRPV4 1 nM (IC50) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (Male)[1]
-
Dosage:0.03, 0.08, and 0.23 mg/kg (i.v. bolus loading dose); 0.6, 1.7, and 5.1 μg/kg/min (continuous i.v. infusion)
-
Administration:i.v. bolus followed by continuous i.v. infusion; 60 min
-
Result:Inhibited the GSK1016790A-induced decrease in MAP and increase in LW/BW ratio in a dose-dependent manner.
Achieved full inhibition of the GSK1016790A-induced decrease in MAP and increase in LW/BW at an infusion dose of 5.1 μg/kg/min.
Chemical Information
-
CAS No. 2215852-91-6
-
Molecular Weight 485.41
-
Formula C20H15F4N3O5S
-
SMILES
FC1=C(C#N)C=CC(O[C@@H]2[C@@](CO)(O)CN(S(C3=C(C#N)C=C(C(F)(F)F)C=C3)(=O)=O)C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Brnardic EJ, et al. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4). Journal of medicinal chemistry. 2018 Nov 08;61(21):9738-9755. [Content Brief]
[2]. Nilsson M, et al. TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists. Journal of medicinal chemistry. 2026 Jul 23;69(14):16926-16948. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GSK3395879 Related Classifications
HY-112202 Related Classifications
Powered by Bioz